Timothy L. Enns - Senior Vice President of Investor Relations, Business Development & Corporate Communications, Senior Vice President of Corporate Communications & Business Development and Vice President of Business Development James S. J. Manuso - Chairman of the Board and Chief Executive Officer Michael Molkentin - Chief Financial Officer, Principal Accounting Officer and Corporate Secretary Robert Corringham - Harren Jhoti - Founder, Chief Executive officer and Director Analysts Boris Peaker - Oppenheimer & Co. Inc., Research Division Thomas Yip - McNicoll, Lewis & Vlak LLC, Research Division Robin Davison - Edison Investment Research Limited PresentationOperator Good day, ladies and gentlemen, and thank you for standing by, and welcome to the Astex Pharmaceuticals Fourth Quarter and Year End 2011 Earnings Conference Call. [Operator Instructions] As a reminder, this conference may be recorded. And now it's my pleasure to turn the call over to Timothy Enns, Senior Vice President, Corporate Communications and Marketing. Sir, the floor is yours. Timothy L. Enns Thank you, operator. Good day and thank you for joining us for Astex Pharmaceuticals 2011 Fourth Quarter and Annual Financial Results conference call. With me today are Dr. James Manuso, Chairman and Chief Executive Officer; Dr. Harren Jhoti, President and member of the Board of Directors; Dr. Martin Buckland, Chief Business Officer; Michael Molkentin, Chief Financial Officer; Dr. Robert Corringham, Vice President of Clinical Development; and Dr. David Smith, Vice President of Regulatory and Quality Affairs. In a few moments, Jim Manuso and Michael Molkentin will deliver remarks on the 2011 fourth quarter and fiscal year financial results and our business outlook for 2012. After prepared comments, we will open the line for questions. Earlier today, we issued a press release with our financial results. A copy of the press release is available in the Investor Relations section of our website at www.astx.com. In addition, this call is being webcast and may be accessed via the Investor Relations section of our website. A webcast replay will be available for 30 days.